In the latest episode of “Patient Perspectives” Podcast, Karl Freemyer, Head of BD at FIECON, a Herspiegel company, talks to Chris Wade, a patient living with chronic lower back pain, whose life changed after a car accident.

In this episode of, Daniel Evans , HEOR Associate at FIECON, speaks with Charlotte Keys, a patient advocate, whose son Lucas was diagnosed with Citrullinaemia Type 1, and Jonathan Alexander Gibson, Campaigns Lead at Metabolic Support UK .

In this episode, Tyler Piazza, BD Director at FIECON, hosts an insightful interview with Kevin Wake, CMR, CHW, M.S., a sickle cell disease patient advocacy leader and a health outcomes industry expert.

Kevin, who was diagnosed with sickle cell disease at nine months old, is now the president of URIEL E OWENS SICKLE CELL DISEASE ASSOCIATION OF THE MIDWEST and serves on the board of directors for the International Consortium for Health Outcomes Measurement (ICHOM).

In this episode Karl Freemyer, BD director at FIECON, is speaking with Emma Chaffin about her experience living with the metastatic breast cancer as a biopharmaceutical executive.

Emma is a resilient breast cancer survivor who was diagnosed with stage 4 breast cancer five years ago at the age of 41. Facing a daunting prognosis and a treatment plan focused on palliative care, she defied the odds, with only a 22% chance of surviving five years.

Von Hippel-Lindau syndrome (VHL), is an inherited condition that brings about tumors in various organs, particularly hemangioblastomas, which are blood vessel tumors found in the brain, spinal cord, and retina.

Listen to FIECON's latest 'Patient Perspectives' podcast with Lauren Weinberg, Senior Associate at FIECON, talking to Frankie Bryant about her journey living with VHL and the impact it has had.

In this podcast, Lily Mumford talks to Lauren Weinberg, Senior Associate at FIECON, about her patient journey, experience living with LHON, and how losing her vision has impacted her life.

Leber hereditary optic neuropathy (LHON) is a rare condition that primarily affects young adults. It causes painless vision loss, typically starting in one eye and later affecting the other eye within a few weeks. Some individuals with LHON may also experience rare neurological problems like nerve issues, tremors, muscle weakness, and movement disorders.

LHON is caused by changes in mitochondrial DNA and is inherited through the maternal line. It is a rare disease affecting about 1 in 50,000 people. Many carriers of LHON do not experience significant vision loss.

However, males are four to five times more likely to lose vision than females. The annual incidence of vision loss in LHON is extremely low, around 1 in 10 million.

In this podcast, David Robins talks to Lauren Weinberg, Senior Associate at FIECON, about the patient journey, his experience as the father of Lexi who lives with Fibrodysplasia Ossificans Progressiva (FOP), and as a family after the FOP diagnosis.

FOP is an ultra-rare genetic condition and is one of the most debilitating conditions known to medicine. FOP causes the soft connective tissue of the body to turn into new bone.  When that occurs over or near joints, or within a muscle, it restricts the person’s movements.  This new bone, or ossification, can mean that the sufferer is eventually no longer able to move the joint.  Once movement has been lost in a part of the body, it is not possible to remove the new bone as that can aggravate the FOP and trigger further bone growth.
FOP is characterised by congenital malformations of the big toes and progressive heterotopic ossification (HO) in specific anatomic patterns. FOP is the most catastrophic disorder of HO in humans. Flare-ups are episodic; immobility is cumulative.  A common mutation in activin receptor IA (ACVR1), a bone morphogenetic protein (BMP) type I receptor, exists in all sporadic and familial cases with a classic presentation of FOP.

There is currently no treatment for FOP so investigating all avenues of research and finding more FOP doctors, who are willing to be educated about FOP, is essential.

• S = Severe speech anomalies
• A = Abnormalities of the palate
• T = Teeth anomalies
• B = Behavioral issues with or without Bone or Brain anomalies

Juliette Vila Sinclair-Spence is a passionate Acanthamoeba keratitis (AK) Warrior and Rare Disease Patient Advocate as well as the Founder and Chairwoman of Acanthamoeba keratitis (AK) Eye Foundation. With her patient voice, she brings personal and first-hand experience of what it means to be affected by Acanthamoeba keratitis as well as its aftermath.

Her goal is to raise awareness about the rare disease Acanthamoeba keratitis by educating contact lens users (Contact lens and water don’t mix!), eye professionals to stop misdiagnosing Acanthamoeba keratitis, understand the impact the disease has, providing the right medical treatment (refer to an expert), support like pain management (excruciating pain) as well as mental support (depression) and encourage all contact lens manufacturers that a “No water" label on all packaging would help the goal.

In this podcast, Guy Lacey, Manager at FIECON,  talks to Juliette about her patient journey since she contracted Acanthamoeba keratitis in 2016 and shares the details of her long and arduous journey to diagnosis and finally treatment. She has devoted much of her time to help others learn more about this disease and has became an advocate for patients, families and providers by creating the Acanthamoeba Keratitis (AK) Eye Foundation.

Acanthamoeba keratitis is a rare but often devastating ocular condition that can lead to severe vision impairment, corneal transplantation, and even enucleation. It is caused by a free living amoeba that is typically found in soil and water, including tap water.

The main risk factor for AK is contact lens wear. AK presents initially with a high degree of pain, often out of proportion to the clinical signs observed. Many times, this condition is misdiagnosed as herpes simplex keratitis.

Our innate immune response can fight the infection, but once the amoebas have breached the corneal epithelium, it is difficult for the immune system to fight these parasites due to the fact the cornea is an immune-privileged tissue. Cysts can remain in a dormant state on corneal tissue for close to 3 years making recurrent infection possible.

José Ángel Aibar became involved in the activities of the Dravet Syndrome Foundation, shortly after one of his sons was diagnosed with Dravet syndrome. He has served as President and CEO since June 2018. 

José is also a member of several rare disease and epilepsy working groups, such as Epag EpiCARE and the Eurordis Digital and Data Advisory Group, as well as a member of the advisory committee of several international projects. and from the industry.

The Dravet Foundation was started  with the aim of promoting, encouraging and connecting the world's leading research centers on Dravet syndrome and other related diseases. The aim is find a drug within three years that eliminates the symptoms and allows us to preserve the cognitive state of patients until a definitive solution for the disease is found.

In this podcast, Jamshaed Siddiqui, Manager at FIECON,  talks to José Ángel Aibar about the patient journey and his experiences as both a parent of a child with Dravet syndrome and as a patient advocacy leader.

Dravet syndrome is a rare and catastrophic form of intractable epilepsy that begins in the first year of life, with an estimated incidence of 1 in 22,000 births.

Dravet syndrome is characterised by frequent, prolonged seizures that can be triggered by high body temperature (hyperthermia) and periods of illness.  As well as seizures, common symptoms include mobility, behavioural, and cognitive abnormalities that develop as the child gets older.

There is no cure for Dravet syndrome. Early diagnosis and treatment may minimise seizure frequency and intensity, but few patients achieve seizure freedom. Without treatment, individuals will continue to have frequent seizures and can suffer from seizure-related accidents and increased risk of mortality.

As a rare disease, Dravet syndrome can be challenging for doctors to detect, and diagnosis is typically supported by genetic testing in children who are suspected of having, or at risk for, the condition but may also be diagnosed based on symptoms.